



Astec LifeSciences Ltd.

**Date:** 30<sup>th</sup> January, 2026

To,

To,

**BSE Limited**

P. J. Towers, Dalal Street, Fort,  
Mumbai – 400 001

**National Stock Exchange of India Limited**

Exchange Plaza, Bandra - Kurla Complex,  
Bandra (East), Mumbai – 400 051

**Ref.:** BSE Scrip Code No. “533138”

**Ref.:** “ASTEC”

**Debt Segment NSE:**

NCD-ASTEC-ISIN: INE563J08023

**Sub.: Outcome of the Board Meeting**

Pursuant to Regulations 30, 33 and 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) read with Schedule III to the said Regulations, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e., on Friday, 30<sup>th</sup> January, 2026 (which commenced at 3.30 p.m. and concluded at 5.25 p.m.), *inter alia*, has approved / noted the following:

**(a) APPROVAL OF THE UNAUDITED FINANCIAL RESULTS (STANDALONE & CONSOLIDATED) FOR THE QUARTER AND NINE MONTHS’ PERIOD ENDED 31<sup>ST</sup> DECEMBER, 2025:**

Upon recommendation of the Audit Committee, the Board of Directors has approved the Unaudited Financial Results (Standalone & Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter and Nine Months’ period ended 31<sup>st</sup> December, 2025, which are enclosed herewith as **Annexure A**.

**(b) NOTING OF THE LIMITED REVIEW REPORTS OF THE STATUTORY AUDITORS FOR THE QUARTER AND NINE MONTHS’ PERIOD ENDED 31<sup>ST</sup> DECEMBER, 2025:**

The Board of Directors took note of the Limited Review Reports of the Statutory Auditors on the Unaudited Financial Results (Standalone & Consolidated) for the Quarter and Nine Months’ period ended 31<sup>st</sup> December, 2025, which are enclosed herewith as **Annexure-B**.

The Limited Review Reports of the Statutory Auditors are with unmodified opinion with respect to the Unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Nine Months’ period ended 31<sup>st</sup> December, 2025.

**(c) NOTING OF RESIGNATION TENDERED BY MS. MUGDHA AMOL KHARE AS THE “CHIEF FINANCIAL OFFICER” OF THE COMPANY WITH EFFECT FROM THE CLOSE OF BUSINESS HOURS ON 6<sup>th</sup> MARCH, 2026:**

The Board has noted the resignation of Ms. Mugdha Amol Khare from the position of “Chief Financial Officer” of the Company with effect from the close of business hours on 6<sup>th</sup> March, 2026. The letter of resignation received from Mrs. Mugdha Amol Khare is enclosed herewith as **Annexure-C**.



Regd. Office :  
“Godrej One”, 3<sup>rd</sup> Floor,  
Pirojshanagar, Eastern Express Highway,  
Vikhroli (East), Mumbai - 400079,  
Maharashtra, India  
Telephone No. : 022-25188010  
Fax No. : 022-22618289  
Email id : astecinfo@godrejastec.com  
Website : www.godrejastec.com  
CIN : L99999MH1994PLC076236

Disclosure required pursuant to Regulation 30 of the Listing Regulations, read with Para A of Part A of Schedule III to the Listing Regulations, with regard to change in Directors and Key Managerial Personnel is given hereunder:

Sr. No.	Disclosure Requirement	Details
1.	Reason for Change, viz. <del>appointment, re-appointment, resignation, removal, death or otherwise</del>	Ms. Mugdha Amol Khare has resigned as the Chief Financial Officer of the Company, with effect from close of business hours on 6 <sup>th</sup> March, 2026 for pursuing opportunities outside.
2.	Date of <del>Appointment/Re-appointment</del> Cessation (as applicable) & <del>term of Appointment / Re-appointment</del>	Resignation will be effective from the close of business hours on 6 <sup>th</sup> March, 2026.
3.	Brief Profile (in case of appointment)	Not Applicable
4.	Disclosure of Relationships between Directors (in case of Appointment of a Director)	Not Applicable

It is further informed that there is no other material reason for the resignation other than the reason mentioned above. The Company has accepted her resignation and she will be relieved from the duties with effect from the close of working hours on 6<sup>th</sup> March, 2026.

**(d) Appointment of Mr. Deepak Jawaharlal Ochani as the “Chief Financial Officer” of the Company with effect from 1<sup>st</sup> April, 2026:**

The Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee, has approved the appointment of Mr. Deepak Jawaharlal Ochani as the “Chief Financial Officer” of the Company with effect from 1<sup>st</sup> April, 2026.

Disclosure required pursuant to Regulation 30 of the Listing Regulations, read with Para A of Part A of Schedule III to the Listing Regulations, with regard to change in Directors and Key Managerial Personnel is given hereunder:

Sr. No.	Disclosure Requirement	Details
1.	Reason for Change, viz. <del>appointment, re-appointment, resignation, removal, death or otherwise</del>	The Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee, has approved the appointment of Mr. Deepak Jawaharlal Ochani as the “Chief Financial Officer” of the Company with effect from 1 <sup>st</sup> April, 2026.



Astec LifeSciences Ltd.

2.	Date of Appointment / <del>Re-appointment</del> <del>Cessation (as applicable) &amp;</del> <del>term of Appointment / Re-</del> <del>appointment</del>	Appointment will be effective from 1 <sup>st</sup> April, 2026.
3.	Brief Profile (in case of appointment)	Mr. Deepak Jawaharlal Ochani is a qualified Chartered Accountant and a member of the Institute of Chartered Accountants of India (ICAI). He has 11+ years of professional experience, of which the last 9 years have been with Godrej Agrovet group. He brings with him extensive expertise in the field of financial management, compliance and governance. He has strong expertise in financial planning and analysis (FP&A), budgeting and cost optimization, working capital and cash flow management, capital allocations & investment decisions and implementing internal control systems.
4.	Disclosure of Relationships between Directors (in case of Appointment of a Director)	Not Applicable

Please take the above information on your records.

Thanking you,

Yours sincerely,

**For Astec LifeSciences Limited**

**Tejashree Pradhan**  
**Company Secretary & Compliance Officer**  
**(FCS 7167)**

**Encl.:** As above



Regd. Office :  
"Godrej One", 3<sup>rd</sup> Floor,  
Pirojshanagar, Eastern Express Highway,  
Vikhroli (East), Mumbai - 400079,  
Maharashtra, India  
Telephone No. : 022-25188010  
Fax No. : 022-22618289  
Email id : astecinfo@godrejastec.com  
Website : www.godrejastec.com  
CIN : L99999MH1994PLC076236

# Annexure-A

## Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

ASTEC

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra  
Website: www.godrejastec.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com  
Statement of Unaudited Standalone Financial Results for the Quarter and Nine Months period ended 31st December, 2025

(Rs. in Lakh)

Sr. No	Particulars	STANDALONE					
		Quarter ended			Year to date figure for the period ended		Year ended
		31/Dec/25	30/Sep/25	31/Dec/24	31/Dec/25	31/Dec/24	31/Mar/25
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operations	12,472.03	7,372.06	9,385.84	28,952.30	26,177.65	38,130.35
II	Other Income	79.36	109.44	189.20	237.46	478.09	555.81
III	<b>Total Income (I+II)</b>	<b>12,551.39</b>	<b>7,481.50</b>	<b>9,575.04</b>	<b>29,189.76</b>	<b>26,655.74</b>	<b>38,686.16</b>
IV	<b>Expenses</b>						
	Cost of materials consumed	8,165.02	5,811.92	6,331.27	19,917.56	16,340.79	24,885.99
	Changes in inventories of finished goods and work-in-progress	126.16	(1,683.66)	(173.06)	(1,109.73)	5,999.18	4,807.63
	Employee benefits expense	1,578.02	1,562.26	1,551.64	4,658.69	4,667.93	6,110.45
	Finance costs	717.67	840.86	992.22	2,663.43	2,630.47	3,670.70
	Depreciation and amortisation expense	1,123.77	1,045.73	1,141.70	3,320.52	3,218.27	4,377.40
	Other expenses	2,203.29	2,349.48	2,249.73	6,852.56	6,341.63	8,945.81
	<b>Total expenses (IV)</b>	<b>13,913.93</b>	<b>9,926.59</b>	<b>12,093.50</b>	<b>36,303.03</b>	<b>39,198.27</b>	<b>52,797.98</b>
V	<b>Loss before exceptional items and tax (III - IV)</b>	<b>(1,362.54)</b>	<b>(2,445.09)</b>	<b>(2,518.46)</b>	<b>(7,113.27)</b>	<b>(12,542.53)</b>	<b>(14,111.82)</b>
VI	Exceptional Items (Refer Note 5)	209.43	-	-	209.43	-	-
VII	<b>Loss before tax (V-VI)</b>	<b>(1,571.97)</b>	<b>(2,445.09)</b>	<b>(2,518.46)</b>	<b>(7,322.70)</b>	<b>(12,542.53)</b>	<b>(14,111.82)</b>
VIII	Tax Expense:						
	(1) Current tax	-	-	-	-	-	-
	(2) Deferred tax expense/(income)	-	-	1,521.55	-	(671.56)	(631.00)
IX	<b>Loss for the period/year from continuing operations (VII-VIII)</b>	<b>(1,571.97)</b>	<b>(2,445.09)</b>	<b>(4,040.01)</b>	<b>(7,322.70)</b>	<b>(11,870.97)</b>	<b>(13,480.82)</b>
X	Loss from discontinuing operations	-	-	-	-	-	-
XI	Tax expense of discontinuing operations	-	-	-	-	-	-
XII	<b>Loss from discontinuing operations (after tax) (X-XI)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XIII	<b>Loss for the period/year (IX + XII)</b>	<b>(1,571.97)</b>	<b>(2,445.09)</b>	<b>(4,040.01)</b>	<b>(7,322.70)</b>	<b>(11,870.97)</b>	<b>(13,480.82)</b>
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	15.48	5.64	-	26.76	40.52	22.56
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	(5.68)
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	<b>Total Comprehensive Loss for the period/year (XIII + XIV)</b> <b>(Comprising loss and Other Comprehensive Income for the period/year)</b>	<b>(1,556.49)</b>	<b>(2,439.45)</b>	<b>(4,040.01)</b>	<b>(7,295.94)</b>	<b>(11,830.45)</b>	<b>(13,463.94)</b>
XVI	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2,228.17	2,228.17	1,961.14	2,228.17	1,961.14	1,961.14
XVII	Other Equity excluding Revaluation Reserve	-	-	-	-	-	21,446.25
XVIII	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinuing operations) (non-annualised) :						
	(1) Basic (in Rs.)	(7.06)	(11.39)	(20.60)	(34.66)	(60.53)	(68.74)
	(2) Diluted (in Rs.)	(7.05)	(11.39)	(20.60)	(34.66)	(60.53)	(68.74)

### Notes:

- The above Financial Results which are published in accordance with Regulations 33 and Regulations 52 (4) read with regulation 63 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Friday, 30th January 2026.
- The Financial Results are in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to limited review by the Statutory Auditors of the Company and they have expressed an unmodified review conclusion.
- The Company has only one reportable segment i.e. Agrochemicals as per Ind AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- On 30th June 2025 and 2nd July 2025, The Rights Issue Committee of the board of directors ("Rights Issue Committee") approved various terms of the Rights Issue and the Letter of Offer respectively, for issue of 28,01,673 fully paid-up Equity Shares at an issue price of Rs.890 per Equity Share (face value of Rs.10 per share and a premium of Rs.880 per share) ("fully paid-up equity shares"). Accordingly, the Rights Issue Committee on 29th July 2025 inter-alia, considered and approved the allotment of 26,69,951 fully paid-up equity shares to eligible equity shareholders on application of "Allotment". There has been no deviation in the use of proceeds of the Rights Issue, from the objects stated in the Offer document.
- On 21st November 2025, the Government of India notified the four Labour Codes consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Group has assessed and disclosed the incremental impact of these changes on the basis of best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India (ICAI). Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Group has presented such incremental impact under "Exceptional Items" in the statement of profit and loss for the period ended 31st December 2025. The incremental impact consisting of gratuity of Rs. 172.80 Lakh and long-term compensated absences of Rs. 36.63 lakh primarily arises due to change in wage definition. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.

For Astec LifeSciences Limited

Burjis N. Godrej

BURJIS GODREJ  
Managing Director

DIN: 08183082

Place : Mumbai

Date : 30th January 2026





**Astec LifeSciences Limited**

Corporate Identity Number : L99999MH1994PLC076236

ASTEC

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.godrejastec.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com

Additional disclosures as per Clause 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

(Rs. in Lakh)

Sr. No	Particulars	STANDALONE					
		Quarter ended			Year to date figure for the period ended		Year ended
		31/Dec/25	30/Sep/25	31/Dec/24	31/Dec/25	31/Dec/24	31/Mar/25
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Current Ratio (refer note 1)	1.02	1.04	0.79	1.02	0.79	0.93
II	Net Worth (in Rs. Lakh)	39,768.20	41,321.70	25,035.60	39,768.20	25,035.60	23,407.39
III	Outstanding redeemable preference shares (quantity and value)	-	-	-	-	-	-
IV	Net profit/(loss) after tax (in Rs. Lakh)	(1,571.97)	(2,445.09)	(4,040.01)	(7,322.70)	(11,870.97)	(13,480.82)
V	Basic Earnings per share	(7.06)	(11.39)	(20.60)	(34.66)	(60.53)	(68.74)
VI	Diluted Earnings per share	(7.05)	(11.39)	(20.60)	(34.66)	(60.53)	(68.74)
VII	Capital Redemption Reserve (in Rs. Lakh)	0.30	0.30	0.30	0.30	0.30	0.30
VIII	Debt Equity ratio (refer note 1)	1.08	0.89	2.06	1.08	2.06	2.37
IX	Debt Service Coverage Ratio (DSCR) (refer note 1)	0.36	(0.05)	(1.86)	(0.08)	(1.64)	(1.15)
X	Interest Service Coverage Ratio (ISCR) (refer note 1)	0.38	(0.66)	(1.90)	(0.50)	(2.28)	(1.48)
XI	Long term debt to working capital (refer note 1)	3.65	3.37	*	3.65	*	*
XII	Bad debts to Account receivable ratio (refer note 1)	-	-	-	-	-	-
XIII	Current liability ratio (refer note 1)	0.71	0.67	0.62	0.71	0.62	0.55
XIV	Total debts to total assets (refer note 1)	0.46	0.42	0.61	0.46	0.61	0.63
XV	Debtors turnover (refer note 1)	3.03	2.34	3.02	2.27	2.42	2.35
XVI	Inventory turnover (refer note 1)	2.83	1.80	2.48	2.29	2.00	2.14
XVII	Operating margin (%)	1.52%	-9.06%	-6.11%	-5.44%	-27.40%	-17.36%
XVIII	Net profit/(loss) margin (%)	-12.60%	-33.17%	-43.04%	-25.29%	-45.35%	-35.35%

\* Working Capital is negative

**1 Formulae for computation of ratios:**

Current ratio : Current assets / Current liabilities

Net Worth: Total equity

Debt Equity ratio : Total Debt / Shareholder's Equity

Debt Service Coverage Ratio : (Net Profit/(loss) after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / (Interest & Lease Payments + Principal Repayments)

Interest service coverage ratio: (Net Profit/(loss) after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / Interest expense

Long term debt to working capital : (Non-current borrowings+Current maturities of long term debt) / (Current Assets - (Current liabilities-Current maturities of long term debt))

Bad debts to Account receivable ratio : Bad debts including provision for doubtful debts / Average Trade receivable.

Current liability ratio : (Current liabilities-Current maturities of Long term Debt) / Total liabilities

Total debts to total assets : Total borrowings / Total assets

Debtors turnover : Net Credit Sales / Average Trade Receivable (annualised)

Inventory turnover : Net Sales/ Average Inventory (annualised).

Operating margin (%): Earnings before Interest, Tax & Depreciation & Amortisation less Other Income/Revenue from Operations

Net Profit/(Loss) margin(%): Net Profit/(Loss) after Tax(after exceptional items)/Revenue from Operations

**2 Pursuant to SEBI Operational Circular for Issue and Listing of Non-Convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper dated 10th August 2021, the Company has listed Commercial Papers on National Stock Exchange (NSE).**

The Company is rated by leading credit agency ICRA and India Ratings & Research. ICRA has assigned the rating "[ICRA] A1+" and "[ICRA] AA-" for its short term facilities (including commercial paper) and long term facilities respectively. India Ratings & Research has assigned "[IND] AA-" for its Non- Convertible Debentures (NCDs).

Burjis N. Godrej





# Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.godrejastec.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com

Statement of Unaudited Consolidated Financial Results for the Quarter and Nine Months period ended 31st December, 2025



(Rs. in Lakh)

Sr. No	Particulars	Consolidated					
		Quarter ended			Year to date figure for the period ended		Year ended
		31/Dec/25 (Unaudited)	30/Sep/25 (Unaudited)	31/Dec/24 (Unaudited)	31/Dec/25 (Unaudited)	31/Dec/24 (Unaudited)	31/Mar/25 (Audited)
I	Revenue from Operations	12,472.03	7,372.06	9,385.84	28,952.30	26,177.65	38,130.35
II	Other Income	81.52	111.56	191.46	243.73	483.75	562.87
III	<b>Total Income (I+II)</b>	<b>12,553.55</b>	<b>7,483.62</b>	<b>9,577.30</b>	<b>29,196.03</b>	<b>26,661.40</b>	<b>38,693.22</b>
IV	<b>Expenses</b>						
	Cost of materials consumed	8,165.02	5,811.92	6,331.26	19,917.56	16,340.78	24,885.98
	Changes in inventories of finished goods and work-in-progress	126.16	(1,683.66)	(173.06)	(1,109.73)	5,999.18	4,807.63
	Employee benefits expense	1,578.02	1,562.26	1,551.64	4,658.69	4,667.93	6,110.45
	Finance costs	716.55	839.74	991.95	2,660.67	2,629.69	3,669.67
	Depreciation and amortisation expense	1,121.92	1,043.88	1,140.22	3,315.21	3,213.80	4,371.45
	Other expenses.	2,203.96	2,350.22	2,250.08	6,854.20	6,342.84	8,946.96
	<b>Total expenses (IV)</b>	<b>13,911.63</b>	<b>9,924.36</b>	<b>12,092.09</b>	<b>36,296.60</b>	<b>39,194.22</b>	<b>52,792.14</b>
V	<b>Loss before exceptional items and tax (III - IV)</b>	<b>(1,358.08)</b>	<b>(2,440.74)</b>	<b>(2,514.79)</b>	<b>(7,100.57)</b>	<b>(12,532.82)</b>	<b>(14,098.92)</b>
VI	Exceptional Items (Refer Note 5)	209.43	-	-	209.43	-	-
VII	<b>Loss before tax (V-VI)</b>	<b>(1,567.51)</b>	<b>(2,440.74)</b>	<b>(2,514.79)</b>	<b>(7,310.00)</b>	<b>(12,532.82)</b>	<b>(14,098.92)</b>
VIII	Tax Expense:						
	(1) Current tax	1.01	0.94	0.66	3.01	2.51	3.91
	(2) Deferred tax expense/(income)	0.01	0.02	1,521.38	(0.09)	(672.07)	(631.66)
IX	<b>Loss for the period/year from continuing operations (VII-VIII)</b>	<b>(1,568.53)</b>	<b>(2,441.70)</b>	<b>(4,036.83)</b>	<b>(7,312.92)</b>	<b>(11,863.26)</b>	<b>(13,471.17)</b>
X	Loss from discontinuing operations	-	-	-	-	-	-
XI	Tax expense of discontinuing operations	-	-	-	-	-	-
XII	<b>Loss from discontinuing operations (after tax) (X-XI)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XIII	<b>Loss for the period/year (IX + XII)</b>	<b>(1,568.53)</b>	<b>(2,441.70)</b>	<b>(4,036.83)</b>	<b>(7,312.92)</b>	<b>(11,863.26)</b>	<b>(13,471.17)</b>
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	15.48	5.64	-	26.76	40.52	22.56
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	(5.68)
	B (i) Items that will be reclassified to profit or loss	(1.68)	0.35	0.28	(1.62)	0.90	0.50
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	<b>Total Comprehensive Loss for the period/year (XIII + XIV) (Comprising Loss) and Other Comprehensive Income for the period/year)</b>	<b>(1,554.73)</b>	<b>(2,435.71)</b>	<b>(4,036.55)</b>	<b>(7,287.78)</b>	<b>(11,821.84)</b>	<b>(13,453.79)</b>
XVI	<b>Net Profit/(loss) attributable to:</b>						
	- Owners	(1,569.54)	(2,442.70)	(4,038.11)	(7,316.02)	(11,866.47)	(13,475.24)
	- Non controlling interests	1.01	1.00	1.28	3.10	3.21	4.07
	<b>Total Comprehensive loss attributable to:</b>	<b>(1,555.74)</b>	<b>(2,436.71)</b>	<b>(4,037.83)</b>	<b>(7,290.88)</b>	<b>(11,825.05)</b>	<b>(13,457.86)</b>
	- Owners	1.01	1.00	1.28	3.10	3.21	4.07
	- Non controlling interests	-	-	-	-	-	-
XVII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2,228.17	2,228.17	1,961.14	2,228.17	1,961.14	1,961.14
XVIII	Other Equity excluding Revaluation Reserve	-	-	-	-	-	21,513.38
XIX	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinuing operations) (non-annualised) :						
	(1) Basic (in Rs.)	(7.04)	(11.35)	(20.59)	(34.63)	(60.51)	(68.71)
	(2) Diluted (in Rs.)	(7.04)	(11.34)	(20.59)	(34.63)	(60.51)	(68.71)

## Notes:

- The above Financial Results which are published in accordance with Regulations 33 and Regulations 52 (4) read with regulation 63 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Friday, 30th January 2026.
- The Financial Results are in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to limited review by the Statutory Auditors of the Company and they have expressed an unmodified review conclusion.
- The Group has only one reportable segment i.e. Agrochemicals as per Ind AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- On 30th June 2025 and 2nd July 2025, The Rights Issue Committee of the board of directors ("Rights Issue Committee") approved various terms of the Rights Issue and the Letter of Offer respectively, for issue of 28,01,673 fully paid-up Equity Shares at an issue price of Rs 890 per Equity Share (face value of Rs 10 per share and a premium of Rs 880 per share) ("fully paid-up equity shares"). Accordingly, the Rights Issue Committee on 29th July 2025 inter-alia, considered and approved the allotment of 26,69,951 fully paid-up equity shares to eligible equity shareholders on application ("Allotment"). There has been no deviation in the use of proceeds of the Rights Issue, from the objects stated in the Offer document.
- On 21st November 2025, the Government of India notified the four Labour Codes consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Group has assessed and disclosed the incremental impact of these changes on the basis of best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India (ICAI). Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Group has presented such incremental impact under "Exceptional Items" in the statement of profit and loss for the period ended 31st December 2025. The incremental impact consisting of gratuity of Rs. 172.80 lakh and long-term compensated absences of Rs. 36.63 lakh primarily arises due to change in wage definition. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.

For Astec LifeSciences Limited

Burjis N. Godrej

BURJIS GODREJ  
Managing Director  
DIN: 08183082  
Place : Mumbai  
Date : 30th January 2026





# Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.godrejastec.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com



Additional disclosures as per Clause 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

(Rs. In Lakh)

Sr. No	Particulars	Consolidated					
		Quarter ended			Year to date figure for the period ended		Year ended
		31/Dec/25 (Unaudited)	30/Sep/25 (Unaudited)	31/Dec/24 (Unaudited)	31/Dec/25 (Unaudited)	31/Dec/24 (Unaudited)	31/Mar/25 (Audited)
I	Current Ratio (refer note 1)	1.02	1.04	0.79	1.02	0.79	0.93
II	Net Worth (in Rs. Lakh)	39,870.62	41,422.36	25,102.07	39,870.62	25,102.07	23,474.52
III	Outstanding redeemable preference shares (quantity and value)	-	-	-	-	-	-
IV	Net profit/(loss) after tax (in Rs. Lakh)	(1,568.53)	(2,441.70)	(4,036.83)	(7,312.92)	(11,863.26)	(13,471.17)
V	Basic Earnings per share	(7.04)	(11.35)	(20.59)	(34.63)	(60.51)	(68.71)
VI	Diluted Earnings per share	(7.04)	(11.34)	(20.59)	(34.63)	(60.51)	(68.71)
VII	Capital Redemption Reserve (in Rs. Lakh)	0.30	0.30	0.30	0.30	0.30	0.30
VIII	Debt Equity ratio (refer note 1)	1.08	0.89	2.05	1.08	2.05	2.36
IX	Debt Service Coverage Ratio (DSCR) (refer note 1)	0.37	(0.05)	(1.85)	(0.08)	(1.64)	(1.15)
X	Interest Service Coverage Ratio (ISCR) (refer note 1)	0.38	(0.66)	(1.90)	(0.50)	(2.28)	(1.48)
XI	Long term debt to working capital (refer note 1)	3.54	3.28	*	3.54	*	*
XII	Bad debts to Account receivable ratio (refer note 1)	-	-	-	-	-	-
XIII	Current liability ratio (refer note 1)	0.71	0.67	0.62	0.71	0.62	0.55
XIV	Total debts to total assets (refer note 1)	0.46	0.42	0.61	0.46	0.61	0.63
XV	Debtors turnover (refer note 1)	3.03	2.34	3.02	2.27	2.42	3.14
XVI	Inventory turnover (refer note 1)	2.83	1.80	2.48	2.29	2.00	2.14
XVII	Operating margin (%)	1.52%	-9.07%	-6.12%	-5.45%	-27.40%	-17.36%
XVIII	Net profit/(loss) margin (%)	-12.58%	-33.12%	-43.01%	-25.26%	-45.32%	-35.33%

\*Working Capital is negative

## 1 Formulae for computation of ratios:

Current ratio : Current assets / Current liabilities

Net Worth: Total equity

Debt Equity ratio : Total Debt / Shareholder's Equity

Debt Service Coverage Ratio : (Net Profit/(loss) after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / (Interest & Lease Payments + Principal Repayments)

Interest service coverage ratio: (Net Profit/(loss) after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / Interest expense

Long term debt to working capital : (Non-current borrowings+Current maturities of long term debt) / (Current Assets - (Current liabilities-Current maturities of long term debt))

Bad debts to Account receivable ratio : Bad debts including provision for doubtful debts / Average Trade receivable.

Current liability ratio : (Current liabilities-Current maturities of Long term Debt) / Total liabilities

Total debts to total assets : Total borrowings / Total assets

Debtors turnover : Net Credit Sales / Average Trade Receivable (annualised)

Inventory turnover : Net Sales/ Average Inventory (annualised).

Operating margin (%): Earnings before Interest, Tax & Depreciation & Amortisation less Other Income/Revenue from Operations

Net Profit/(Loss) margin(%): Net Profit/(Loss) after Tax(after exceptional items)/Revenue from Operations

## 2 Pursuant to SEBI Operational Circular for Issue and Listing of Non-Convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper dated 10th August 2021, the Company has listed Commercial Papers on National Stock Exchange (NSE).

The Company is rated by leading credit agency ICRA and India Ratings & Research. ICRA has assigned the rating "[ICRA] A1+" and "[ICRA] AA-" for its short term facilities (including commercial paper) and long term facilities respectively. India Ratings & Research has assigned "[IND] AA-" for its Non-Convertible Debentures (NCDs).

Burjis N. Godrej





# **B S R & Co. LLP**

Chartered Accountants

14th Floor, Central B Wing and North C Wing  
Nesco IT Park 4, Nesco Center  
Western Express Highway  
Goregaon (East), Mumbai – 400 063, India  
Telephone: +91 (22) 6257 1000  
Fax: +91 (22) 6257 1010

**Limited Review Report on unaudited standalone financial results of Astec LifeSciences Limited for the quarter ended 31 December 2025 and year to date results for the period from 01 April 2025 to 31 December 2025 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended**

## **To the Board of Directors of Astec LifeSciences Limited**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Astec LifeSciences Limited (hereinafter referred to as "the Company") for the quarter ended 31 December 2025 and year to date results for the period from 01 April 2025 to 31 December 2025 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended, including the manner in which it is to be disclosed, or that it





B S R & Co. LLP

**Limited Review Report (Continued)**  
**Astec LifeSciences Limited**

contains any material misstatement.

For **B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No.: 101248W/W-100022



**Rahul Choudhary**

*Partner*

Mumbai

30 January 2026

Membership No.: 408408

UDIN:26408408RXOVCG1611

**Limited Review Report on unaudited consolidated financial results of Astec LifeSciences Limited for the quarter ended 31 December 2025 and year to date results for the period from 01 April 2025 to 31 December 2025 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended**

**To the Board of Directors of Astec LifeSciences Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Astec LifeSciences Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 31 December 2025 and year to date results for the period from 01 April 2025 to 31 December 2025 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended.
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



**Limited Review Report (Continued)**

**Astec LifeSciences Limited**

6. We did not review the interim financial information of One Subsidiary included in the Statement, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 4.86 lakhs and Rs. 14.37 lakhs, total net profit after tax (before consolidation adjustments) and total comprehensive income (before consolidation adjustments) of Rs. 2.93 lakhs and Rs. 9.02 lakhs, for the quarter ended 31 December 2025 and for the period from 01 April 2025 to 31 December 2025 respectively, as considered in the Statement. These interim financial information has been reviewed by other auditor whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

7. The Statement includes the interim financial information of One Subsidiary which has not been reviewed, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. Nil, total net profit after tax (before consolidation adjustments) and total comprehensive income (before consolidation adjustments) of Rs. Nil, for the quarter ended 31 December 2025 and for the period from 01 April 2025 to 31 December 2025 respectively, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

**For B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No.:101248W/W-100022



**Rahul Choudhary**

*Partner*

Mumbai

30 January 2026

Membership No.: 408408

UDIN:26408408ZZTCIK7477



**Limited Review Report (Continued)**  
**Astec LifeSciences Limited**

**Annexure I**

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Astec LifeSciences Limited	Holding Company
2	Behram Chemicals Private Limited	Subsidiary Company
3	Comercializadora Agricola Agroastrachem Cia Ltda	Subsidiary Company



Date: 30<sup>th</sup> January, 2026

To,

**Astec LifeSciences Limited**

"Godrej One", 3<sup>rd</sup> Floor,  
Pirojshanagar, Eastern Express Highway,  
Vikhroli (East), Mumbai,  
Maharashtra, India, 400079

**Sub: Resignation as the "Chief Financial Officer" of Astec LifeSciences Limited**

Dear Board Members,

I, Mugdha Amol Khare, wish to resign from the position of "Chief Financial Officer" of Astec LifeSciences Limited ("the Company") with effect from the close of the business hours on 6<sup>th</sup> March, 2026, for pursuing career opportunities outside. I further confirm that there are no other material reasons for my resignation (reasons other than the reason stated above).

I thank the Members of the Board of Directors of the Company for their guidance and support during my tenure as the "Chief Financial Officer" of the Company, with a request to accept my resignation.

Kindly acknowledge the receipt of this resignation letter and arrange to submit the necessary e-forms with the office of Registrar of Companies – Mumbai in compliance with the provisions of the Companies Act, 2013.

Thanking you,

Yours faithfully,



**Mugdha Amol Khare**  
**(Chief Financial Officer)**

Place: Mumbai